Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Wenbing Duan, Qi Chen, WenJing Yu, Jinsong Jia, Jing Wang, Xiaolu Zhu, Ting Zhao, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Hongxia Shi, Ying-Jun Chang, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2024-206400

Published: 2024

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

Xiaoshuai Zhang, Zongru Li, Ya-Zhen Qin, Robert Peter Gale, Yueyun Lai, Hongxia Shi, Xiao Jun Huang, Qian Jiang

Blood (2022) 140 (Supplement 1): 9611–9613.

https://doi.org/10.1182/blood-2022-169397

Published: 2022

Journal Articles

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Hao Jiang, Jing Liu, Xiaohong Liu, Jinsong Jia, Lizhong Gong, Shengye Lu, Xiaojun Huang, Jing Wang, Xiaosu Zhao, Yueyun Lai, Hongxia Shi, Yingjun Chang, Guorui Ruan

Blood (2021) 138 (Supplement 1): 2320.

https://doi.org/10.1182/blood-2021-149493

Published: 2021

Journal Articles

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Jing Wang, MD, Jinsong Jia, Xiaohong Liu, Lizhong Gong, Shengye Lu, Yu Wang, Lanping Xu, Xiaohui Zhang, Chenhua Yan, Yueyun Lai, Xiaosu Zhao, PhD, Yazhen Qin, Guorui Ruan, Yingjun Chang, Hongxia Shi, Kaiyan Liu, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140977

Published: 2020

Journal Articles

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Wenbing Duan, Xiaohong Liu, Jinsong JIA, MDPhD, Jing Wang, MD, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, PhD, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141905

Published: 2020

Journal Articles

Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML

Hao Jiang, Xiaojun Huang, Chunjian Wang, Lizhong Gong, Jinsong Jia, Xiaohong Liu, Yu Wang, Chenhua Yan, Yingjun Chang, Xiaosu Zhao, PhD, Hongxia Shi

Blood (2019) 134 (Supplement_1): 1378.

https://doi.org/10.1182/blood-2019-122875

Published: 2019

Journal Articles

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, MD, Qian Jiang, MD

Blood (2019) 134 (Supplement_1): 2940.

https://doi.org/10.1182/blood-2019-130081

Published: 2019

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Qian Jiang, Yazhen Qin, Yueyun Lai, Hao Jiang, Jing Wang, Hongxia Shi, MD, Xiaojun Huang, M.D Ph.D

Blood (2013) 122 (21): 5188.

https://doi.org/10.1182/blood.V122.21.5188.5188

Published: 2013

Journal Articles

Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies.

Xiao Jun Huang, MD, PhD, Lan-Ping Xu, Kai yan Liu, Dai-Hong Liu, Yu Wang, Huan Chen, Yu-Hong Chen, Wei Han, Jing-Zhi Wang, Yao Chen, Xiao-Hui Zhang, Hongxia Shi, MD, Feng-Rong Wang, Fei-Fei Tang

Blood (2009) 114 (22): 1197.

https://doi.org/10.1182/blood.V114.22.1197.1197

Published: 2009

NARROW

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only